Sensory Protein Expression and Urethral Mucosal Dysfunction in the Pathogenesis of Male Bladder Neck Dysfunction and Benign Prostatic Obstruction - 86



Lee Yu Khun, Jiang Yuan-Hong, Kuo Hann-Chorng Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

AIMS of Study

Bladder outlet obstruction (BOO) could be caused by anatomical (eg. benign prostatic obstruction, BPO) or functional (eg. bladder neck dysfunction, BND) etiologies. The dysfunction of urethra might play an important role in the pathophysiology of BOO. This study investigated the sensory proteins in urethral mucosa between BPO and BND.

METHODS

We prospectively investigated urethra mucosal tissue obtained from the operations of transurethral incision and resection in 32 BND and 27 BPO patients, respectively. The specimen was divided into bladder neck (BN) and prostatic urethra two parts for comparison. The expressions of α 1A and β 3 adrenoreceptor, M2 and M3 muscarinic receptors, TGF- β , and TRPV1 by Western blotting were compared between BPO and BND patients. In BND patients, urethral sensory protein expressions and autonomic nervous system (ANS) function evaluated with heart rate variability (HRV) were also compared between surgical success and failure groups.

RESULTS

BPO patients had higher expression of α 1A adrenoreceptor in BN but lower expression of M2 muscarinic receptor in prostatic urethra than BND patients (Table 1). In BND patients, success group had higher expressions of α 1A adrenoreceptor and TRPV1 in both BN and prostatic urethra, higher expression of M3 muscarinic receptor in BN, and a higher LF/ HF (low frequency power/ high frequency power) ratio in HRV than failure group (Table 2). A positive correlation was noted between the expression of β 3 adrenoreceptor in BN and HF power in HRV (r=0.570), and also between the expression of TGF- β in BN and LF/ HF ratio in HRV (r=0.525).

 Table 1. Sensory proteins expressions (Western blotting analysis) in the urethral mucosa of patients with BPO and BND.

	BPO (N=23)	BND (N=32)	P value
Bladder neck			
α1A	1.06 ± 0.60	0.72 ± 0.51	0.027
adrenoreceptor			
β3 adrenoreceptor	0.55 ± 0.36	0.57±0.27	0.838
M2 muscarinic receptor	1.14 ± 0.72	1.45 ± 0.81	0.147
M3 muscarinic receptor	0.15 ± 0.08	0.16±0.11	0.897
TGF-β	0.71±0.51	0.80 ± 0.48	0.520
TRPV1	1.42 ± 0.60	1.53 ± 0.53	0.485
Prostatic urethra			
α1A adrenoreceptor	0.88 ± 0.60	0.72 ± 0.48	0.283
β3 adrenoreceptor	0.50 ± 0.29	0.49 ± 0.24	0.909
M2 muscarinic receptor	1.11±0.73	1.52 ± 0.73	0.047
M3 muscarinic receptor	0.18 ± 0.08	0.22 ± 0.14	0.226
TGF-β	0.71 ± 0.52	0.82 ± 0.48	0.402
TRPV1	1.45 ± 0.54	1.59±0.49	0.304

Table 2. Heart rate variability and sensory proteins expressions in the urethral mucosa between surgical success and failure groups of BND patients.

	Success	Failure	Р
	(N=20)	(N=8)	value
HRV			
LF Power	142.53 ± 194.59	17.40±16.26	0.175
HF Power	66.60 ± 52.53	94.40±142.17	0.517
LF/ HF ratio	2.23 ± 1.69	0.41 ± 0.36	0.030
Sensory			
proteins			
expressed in			
bladder neck	0.00.00 50	0.00.001	0.004
α1A adrenoreceptor	0.89 ± 0.50	0.32±0.21	0.004
β3	0.55±0.23	0.61±0.38	0.608
adrenoreceptor	0.33±0.23	0.01±0.58	0.008
M2 muscarinic	1.44±0.79	1.04±0.52	0.201
receptor			
M3 muscarinic	0.18 ± 0.11	0.10±0.06	0.046
receptor			
TGF-β	0.92±0.46	0.55±0.44	0.059
TRPV1	1.67±0.54	1.18±0.44	0.026
Sensory			
proteins			
expressed in prostatic			
urethra			
αlA	0.79±0.45	0.34±0.28	0.016
adrenoreceptor	0.77±0.45	0.54±0.20	0.010
β3	0.49±0.27	0.48±0.17	0.931
adrenoreceptor			
M2 muscarinic	1.58 ± 0.77	1.08±0.57	0.136
receptor			
M3 muscarinic	0.22±0.15	0.20 ± 0.09	0.751
receptor TGF-β	0.02+0.44	0 66+0 52	0.175
TRPV1	0.93 ± 0.44	0.66 ± 0.52	0.175
	1.69 ± 0.43	1.26 ± 0.60	0.040

CONCLUSIONS

BPO and BND patients had different sensory protein expressions in urethra mucosa, indicating their different pathophysiology. In BND patients, urethral mucosal dysfunction with distinct sensory protein expressions and ANS dysfunction might play important roles in the treatment outcome and reflex the complex pathophysiology.